Project Grant R44CA217587

The federal Project Grant award R21CA282561, with $219,024 in funding from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395), aims to test the beneficial effects of the CSP7 peptide in inhibiting radiation-induced lung injury (RILI) and resolving radiation-induced pulmonary fibrosis (RIPF) in mice. This research will explore the potential of CSP7 as a novel intervention to protect cancer patients undergoing thoracic radiation therapy from the debilitating side...

This $399,499 Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of Liquid Biotech's TELOMESCAN circulating tumor cell (CTC) assay for monitoring non-small cell lung cancer (NSCLC) patients undergoing radiation and immunotherapy. The key products and services to be delivered through this funding include: 1) Developing a clinical prototype of the TELOMESCAN assay with automated analysis to...

This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $321,304 to PDX Pharmaceuticals Inc. to advance the commercialization readiness of their nanoparticle-based immunotherapy, ARAC-02, for the treatment of non-small cell lung cancer (NSCLC). The key products and services being delivered through this award are: 1) Protecting the intellectual property (IP) of the ARAC-02 product and the broader PDX-NP...

The National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded a $1,999,108 Project Grant to Orbit Genomics, Inc. to develop a high-sensitivity, high-specificity lung cancer subtyping diagnostic test. The goal is to create a test that can accurately differentiate between small cell lung carcinoma (SCLC), non-small cell lung carcinoma (NSCLC), and NSCLC subtypes (squamous cell carcinoma, adenocarcinoma, large cell carcinoma). This...

The federal Project Grant award "OPTIMIZING SURVEILLANCE IN LUNG CANCER SURVIVORS WITH NOVEL IMAGING BIOMARKERS AND DEEP-LEARNING (OPTIMAL)" is funded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program. The $968,999 award will be used by the University of North Carolina at Chapel Hill (UNC-CH) to examine 12,000 individuals treated surgically for stage I or II non-small cell lung cancer from 2015 to 2025, with follow-up through...

This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $556,684 to support the development of a bioengineered therapeutic device for the prevention of lymphedema. The primary awardee is the Palo Alto Veterans Institute for Research (PAVIR), a nonprofit research organization, with a sub-award to Fibralign Corporation, a small business. The objective of this project is to optimize the structural...

This Project Grant award, funded by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), supports the development and evaluation of an innovative approach to target mesothelioma, a devastating form of cancer. The $696,447 award will enable researchers at the University of Virginia to build on their discovery of a novel tumor-selective antibody that binds to the CD46 epitope, which is highly expressed across all major mesothelioma subtypes. The research aims to...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $1,625,000.00 to Onc.ai, Inc. to validate a radiomics-based multi-modal predictive model for assessing response to PD-1/PD-L1 immunotherapy in patients with stage IV non-small cell lung cancer. The key objectives are to: 1) Prospectively validate the predictive accuracy of the radiomics-based model in a multi-institutional clinical study; 2) Evaluate the model's...

The National Cancer Institute (NCI) awarded a 5-year, $657,536 Project Grant (CFDA 93.393 Cancer Cause and Prevention Research) to the University of North Carolina at Chapel Hill to conduct research on the burden and impact of false-positive results from lung cancer screening using low-dose computed tomography (LDCT). The key objectives are to: 1) identify attitudes, knowledge, and experiences with false-positive LDCT results among patients and clinicians; 2) determine factors affecting...

This $238,824 National Cancer Institute (NCI) Cancer Research Manpower (CFDA 93.398) Project Grant, awarded to The General Hospital Corporation (doing business as Massachusetts General Hospital) on December 1, 2024, will fund a two-year research fellowship to investigate the impact of lung cancer staging procedures on treatment decisions and quality-adjusted life years. The project aims to compare the ability of two lymph node biopsy procedures, endobronchial ultrasound guided transbronchial...